Population pharmacokinetic model for gatifloxacin in pediatric patients

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1246-1252

  Rubino, Christopher M ^a,j   Capparelli, Edmund V ^b   Bradley, John S ^c   Blumer, Jeffrey L ^d,e   Kearns, Gregory L ^f,g   Reed, Michael ^d,e   Jacobs, Richard F ^h   Cirincione, Brenda ^a   Grasela, Dennis M ⁱ  

^a Albany Medical College   (United States)

^b VCSD Pediatric ACTG Pharmacology Laboratory   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^g CHILDREN S MERCY HOSPITAL   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j ORDWAY RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; BODY WEIGHT; CALCULATION; CHILD; COMPARTMENT MODEL; DATA ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; POPULATION MODEL; POPULATION PHARMACOKINETIC MODEL; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMPUTER SIMULATION; FLUOROQUINOLONES; HUMANS; INFANT; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD;

EID: 34247173459     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00685-06     Document Type: Article

References (34)

1. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
2. Ambrose, P. G., S. M. Bhavnani, and R. C. Owens, Jr. 2003. Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. N. Am. 17:529-543.
3. Arguedas, A., L. Sher, E. Lopez, X. Saez-Llorens, K. Hamed, K. Skuba, and P. F. Pierce. 2003. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr. Infect. Dis. J. 22:949-955.
4. Beal, S. L., and L. B. Sheiner. 1998. NONMEM users guides-part VII: conditional estimation methods. NONMEM Project Group, University of California, San Francisco.
5. Bellissant, E., V. Sebille, and G. Paintaud. 1998. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin. Pharmacokinet. 35:151-166.
6. Boeckman, A. J., S. L. Beal, and L. B. Sheiner. 1994. NONMEM users guides-part V: introductory guide. NONMEM Project Group, University of California, San Francisco.
7. Bradley, J. S., M. N. Dudley, and G. L. Drusano. 2003. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr. Infect. Dis. J. 22:982-992.
8. Reference deleted.
9. Capparelli, E. V., M. D. Reed, J. S. Bradley, G. L. Kearns, R. F. Jacobs, B. D. Damle, J. L. Blumer, and D. M. Grasela. 2005. Pharmacokinetics of gatifloxacin in infants and children. Antimicrob. Agents Chemother. 49:1106-1112.
10. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
11. Fantin, B., J. Leggett, S. Ebert, and W. A. Craig. 1991. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob. Agents Chemother. 35:1413-1422.
12. Gehan, E. A., and S. L. George. 1970. Estimation of human body surface area from height and weight. Cancer Chemother. Rep. 54:225-235.
13. Grasela, D., C. Rubino, F. Lacreta, A. Arguedas, L. Sher, E. Lopez, X. Saez-Lorenz, M. Swingle, B. Cirincione, M. Sokolowski, and P. Pierce. 2001. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-37.
14. Grasela, D. M. 2000. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin. Infect. Dis. 31:S51-S58.
15. Hamed, K. A., A. Arguedas, X. Saez-Llorens, A. Rodriguez, J. Y. Yang, P. Pierce, and R. Echols. 2003. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. G-1848.
16. Hamed, K. A., L. Sher, A. Arguedas, M. Husseman, D. Biswas, P. Pierce, and R. Echols. 2003. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. G-1850.
17. Reference deleted.
18. Huczko, E., B. Conetta, D. Bonner, L. Valera, T. Stickle, A. Macko, and J. Fung-Tomc. 2000. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998. Int. J. Antimicrob. Agents 16:401-405.
19. Jones, R. N., C. M. Rubino, S. M. Bhavnani, and P. G. Ambrose. 2003. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47:292-296.
20. Jones, R. N., D. J. Biedenbach, M. E. Erwin, M. L. Beach, and M. A. Pfaller. 1999. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J. Clin. Microbiol. 37:1999-2002.
21. Jones, R. N., D. M. Johnson, M. E. Erwin, M. L. Beach, D. J. Biedenbach, M. A. Pfaller, et al. 1999. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Diagn. Microbiol. Infect. Dis. 34:91-98.
22. Lacreta, F. P., G. D. Kollia, G. Duncan, and D. M. Grasela. 2001. Lack of effect of food on the bioavailability of gatifloxacin. J. Infect. Dis. Pharmacother. 4:43-54.
23. LaCreta, F. P., S. Kaul, G. D. Kollia, G. Duncan, D. M. Randall, and D. M. Grasela. 2000. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. Pharmacotherapy 20:59S-66S.
24. Leibovitz, E., L. Piglansky, S. Raiz, D. Greenberg, K. A. Hamed, J. M. Ledeine, J. Press, A. Leiberman, R. M. Echols, P. F. Pierce, M. R. Jacobs, and R. Dagan. 2003. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr. Infect. Dis. J. 22:943-949.
25. Leibovitz, E., C. Rubino, B. Damle, B. Cirincione, G. Duncan, D. Grasela, K. Hamed, R. Echols, and R. Dagan. 2003. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-14.
26. Lober, S., S. Ziege, M. Rau, G. Schreiber, A. Mignot, P. Koeppe, and H. Lode. 1999. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob. Agents Chemother. 43:1067-1071.
27. Mouton, J. W., M. L. van Ogtrop, D. Andes, and W. A. Craig. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob. Agents Chemother. 43:2473-2478.
28. Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640.
29. Reference deleted.
30. Schwartz, G. J., L. P. Brion, and A. Spitzer. 1987. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. N. Am. 34:571-590.
31. Sheiner, L. B. 1984. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab. Rev. 15:153-171.
32. Tett, S. E., N. H. G. Holford, and A. J. McLachlan. 1998. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Inf. J. 32:693-710.
33. Vozeh, S., J. L. Steimer, M. Rowland, P. Morselli, F. Mentre, L. P. Balant, and L. Aarons. 1996. The use of population pharmacokinetics in drug development. Clin. Pharmacokinet. 30:81-93.
34. Wise, R., J. M. Andrews, J. P. Ashby, and J. Marshall. 1999. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J. Antimicrob. Chemother. 44:701-704.